Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT ID: NCT00109044
Last Updated: 2012-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
540 participants
INTERVENTIONAL
2005-03-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979
Escitalopram in Adult Patients With Major Depressive Disorder
NCT00668525
Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
NCT00239954
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
NCT00384436
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient's current depressive episode must be at least 12 weeks in duration.
Exclusion Criteria
* Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.
* Patients who are considered a suicide risk.
* Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southwest Health, Ltd
Phoenix, Arizona, United States
Alpine Clinical Research
Boulder, Colorado, United States
Radiant Research, Inc.
Denver, Colorado, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Cunningham Clinical Research, LLC
Edwardsville, Illinois, United States
Midwest Center for Neurobiological Medicine
Oakbrook Terrace, Illinois, United States
Capital Clinical Research Associates
Rockville, Maryland, United States
Summit Research Network (Michigan), Inc.
Okemos, Michigan, United States
CNS Research Institute
Clementon, New Jersey, United States
Center for Emotional Fitness
Moorestown, New Jersey, United States
Eastside Comprehensive Medical Center
New York, New York, United States
Piedmont Medical Research Associates, Inc.
Winston-Salem, North Carolina, United States
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States
Claghorn-Lesem Research Clinic
Bellaire, Texas, United States
Croft Group Research Center
San Antonio, Texas, United States
Dominion Clinical Research
Midlothian, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Summit Research Network (Seattle), LLC
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCT-MD-35
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.